Mavacamten

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Mavacamten
Accession Number
DB14921
Type
Small Molecule
Groups
Investigational
Description

Mavacamten is under investigation in clinical trial NCT03442764 (A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)).

Structure
Thumb
Synonyms
Not Available
Categories
UNII
QX45B99R3J
CAS number
1642288-47-8
Weight
Average: 273.336
Monoisotopic: 273.147726864
Chemical Formula
C15H19N3O2
InChI Key
RLCLASQCAPXVLM-NSHDSACASA-N
InChI
InChI=1S/C15H19N3O2/c1-10(2)18-14(19)9-13(17-15(18)20)16-11(3)12-7-5-4-6-8-12/h4-11,16H,1-3H3,(H,17,20)/t11-/m0/s1
IUPAC Name
6-{[(1S)-1-phenylethyl]amino}-3-(propan-2-yl)-1,2,3,4-tetrahydropyrimidine-2,4-dione
SMILES
CC(C)N1C(=O)NC(N[C@@H](C)C2=CC=CC=C2)=CC1=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
57876199

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Active Not RecruitingTreatmentHypertrophic Cardiomyopathy (HCM)1
2CompletedTreatmentNon-obstructive Hypertrophic Cardiomyopathy1
2, 3Enrolling by InvitationTreatmentHypertrophic Cardiomyopathy (HCM) / Non-obstructive Hypertrophic Cardiomyopathy / Obstructive Hypertrophic Cardiomyopathy1
3Active Not RecruitingTreatmentObstructive Hypertrophic Cardiomyopathy1
3Not Yet RecruitingTreatmentHOCM, Hypertrophic Obstructive Cardiomyopathy1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.226 mg/mLALOGPS
logP2.1ALOGPS
logP2.21ChemAxon
logS-3.1ALOGPS
pKa (Strongest Acidic)10.7ChemAxon
pKa (Strongest Basic)-3.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area61.44 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity86.78 m3·mol-1ChemAxon
Polarizability29.92 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 08:35 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates